Long-term serum ferritin dynamics in patients receiving antiviral treatment for hepatitis C virus infection
Yu‐Ping Chang, Chiuan-Bo Huang, Jia‐Horng Kao, Tung‐Hung Su, Shang‐Chin Huang, Tai‐Chung Tseng, Pei‐Jer Chen, Chun‐Jen Liu, Chen‐Hua Liu
Abstract
BACKGROUND: ) and factors associated with trends in changes among patients undergoing treatment for hepatitis C virus (HCV). METHODS: Serum ferritin levels were assessed biannually in 1538 participants undergoing direct-acting antivirals (DAAs) or peginterferon plus ribavirin (PR) with a median of follow-up of 5.0 years after off-treatment week 12. We compared the differences in time-dependent slope coefficients of serum ferritin levels for factors of interest using the generalized estimating equations to identify predictors associated with favorable serum ferritin evolution. RESULTS: , the ferritin evolution was not affected by DAA or PR treatment (crude slope coefficient difference: 3.33 ng/mL/year [95% CI: 12.78 to 6.12], p = 0.49). Absence of MASLD was associated with favorable ferritin evolution (adjusted slope coefficient difference: 2.86 ng/mL/year [95% CI: 5.39 to -0.33], p = 0.021). CONCLUSION: .